A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Latest Information Update: 06 Dec 2023
At a glance
- Drugs CT 125A (Primary) ; Cyclophosphamide; Fludarabine
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 02 Mar 2021 New trial record